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Background: Cancer diagnostics and surgery have been disrupted by the response of health care services to the
coronavirus disease 2019 (COVID-19) pandemic. Progression of cancers during delay will impact on patients’ long-
term survival.
Patients and methods: We generated per-day hazard ratios of cancer progression from observational studies and
applied these to age-specific, stage-specific cancer survival for England 2013e2017. We modelled per-patient delay
of 3 and 6 months and periods of disruption of 1 and 2 years. Using health care resource costing, we contextualise
attributable lives saved and life-years gained (LYGs) from cancer surgery to equivalent volumes of COVID-19
hospitalisations.
Results: Per year, 94 912 resections for major cancers result in 80 406 long-term survivors and 1 717 051 LYGs. Per-
patient delay of 3/6 months would cause attributable death of 4755/10 760 of these individuals with loss of 92
214/208 275 life-years, respectively. For cancer surgery, average LYGs per patient are 18.1 under standard
conditions and 17.1/15.9 with a delay of 3/6 months (an average loss of 0.97/2.19 LYGs per patient), respectively.
Taking into account health care resource units (HCRUs), surgery results on average per patient in 2.25 resource-
adjusted life-years gained (RALYGs) under standard conditions and 2.12/1.97 RALYGs following delay of 3/6 months.
For 94 912 hospital COVID-19 admissions, there are 482 022 LYGs requiring 1 052 949 HCRUs. Hospitalisation of
community-acquired COVID-19 patients yields on average per patient 5.08 LYG and 0.46 RALYGs.
Conclusions: Modest delays in surgery for cancer incur significant impact on survival. Delay of 3/6 months in surgery for
incident cancers would mitigate 19%/43% of LYGs, respectively, by hospitalisation of an equivalent volume of
admissions for community-acquired COVID-19. This rises to 26%/59%, respectively, when considering RALYGs. To
avoid a downstream public health crisis of avoidable cancer deaths, cancer diagnostic and surgical pathways must
be maintained at normal throughput, with rapid attention to any backlog already accrued.
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Following the first case reports in Hubei province, China,
in late 2019, a pandemic of coronavirus disease 2019 (COVID-
19) was declared by the World Health Organization in March
2020. Although COVID-19 causes minimal or mild illness in
most, a small but appreciable proportion of individuals
require oxygen therapy and often admission to an intensive
care unit (ICU). The ensuing unprecedented pressure on
hospital wards and ICUs has necessitated rapid re-https://doi.org/10.1016/j.annonc.2020.05.009 1065
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of COVID-19 cases with deprioritisation of non-emergency
clinical services, including diagnostics and elective
specialist surgery. Concurrently, lockdown of the population
has impacted dramatically on presentation and referral of
symptomatic patients from primary into secondary care.1
For patients with cancer, delay of surgery has the real
potential to increase the likelihood of metastatic disease,
with some patients’ tumours progressing from being curable
(with near-normal life expectancy) to noncurable (with
limited life expectancy).2 The situation has been further
exacerbated by recent safety concerns regarding aerosol
generation from endoscopy, cystoscopy and surgery.3,4
Current projections indicate that COVID-19-related
disruption may well last for 18 months, until there is
either long-term effective containment in the population or
large-scale vaccination. To inform health care prioritisation
and resource allocation, we have examined the impact on
cancer outcomes of different periods of delay of cancer
surgery with disruption extending over variable periods,
comparing resource-weighted outcomes with hospital
management of COVID-19 patients.METHODS
Data sources
Number and age-specific 5-year net survival of cancer pa-
tients that had potentially curative surgical resections for
nonhematological malignancies between 2013 and 2017
were obtained from the Public Health England National
Cancer Registration Service.5 As well as cancer stage at
diagnosis for each cancer type, breast tumour receptor data
allowed subtyping of these cancers as ERþ HER2, HERþ
(any), ER HER2 and other. Estimates for nosocomial
infection rates, median duration of hospital stay for each
cancer type, staffing of theatres, ICU and surgical wards were
based on information from three large UK surgical oncology
centres. Patterns of administration of adjuvant systemic
anticancer therapy (SACT) were based on oncologist-
reviewed standard practice guidance.6 ICU COVID-19 mor-
tality, distribution by age and duration of stay and proportion
referred into ICU were obtained from ICNARC (Intensive Care
National Audit and Research Centre) and data from hospi-
talised UK cases.7,8 Because of lack of UK data, data from
Wuhan were used as the basis for the age distribution of
community infection, age-specific likelihoods of admission
from community to hospital and case fatality rates for non-
ICU COVID-19 patients9,10 (see supplementary Table S1,
available at Annals of Oncology online).Analysis
Impact of COVID-associated delay on cancer outcomes.We
used published data from studies examining the impact on
overall survival from delay in cancer surgery to estimate per-
day hazard ratios (HRs) associated with delay for different
cancers (the ‘Fatality HR’).11e21 We had sufficient data to
generate Fatality HRs for three tumour types and assigned1066 https://doi.org/10.1016/j.annonc.2020.05.009these to other tumours, based on comparability of 5-year
survival as low (>90%), moderate (50%e90%) or high
(<50%) progressiveness tumours.5 Because we were unable
to identify any suitable observational data for tumours of
high progressiveness (e.g. oesophageal, gastric), we applied
the Fatality HR from tumours of moderate progressiveness;
this is likely to be a conservative assumption (supplementary
Table S2, available at Annals of Oncology online).
By accounting for COVID-related postsurgical mortality
and changes in SACT, we adjusted 5-year net survival figures
for each cancer for surgical patients under ‘standard’ care to
estimate ‘current’ 5-year net survival. To model outcomes of
surgery ‘post-delay’, we apply to standard 5-year net sur-
vival the Fatality HR relating to the specified number of days
of delay, again including COVID-related postsurgical mor-
tality. Based on estimates from a UK surgical oncology
centre, supported by the literature, we applied a current
per-day rate of nosocomial infection of 5%. Assuming
improvement in cold protocols, we modelled reduction in
this rate over time. We estimated COVID-associated surgical
mortality based on per-day rate of nosocomial infection,
operation-specific duration of postsurgical admission and
age-specific mortality from infection. We estimated COVID-
19-associated mortality for SACT administration, based on
per-day rate of nosocomial infection, the frequency of SACT
scheduling, increased risk associated with immunosup-
pression and age-specific mortality from infection. We
assumed, where standard of care, that SACT offers a uni-
form survival benefit (5% in stage 1, 7.5% in stage 2 and
10% in stage 3) and administration would only continue
where this benefit exceeds COVID-related mortality.
We used mean life expectancies per 10-year age group to
calculate life-years gained (LYGs), averaged per patient. We
examined reduction in overall survival and LYGs, comparing
surgery under standard care, current conditions and post-
delay, by cancer type and by age and stage. Using 2013e
2017 surgical workload data, we calculated, across all adult
cancers examined, the total number of deaths and life-years
lost attributable to delay. To address possible scenarios, we
considered per-patient delay of up to 6 months, and 1- and
2-year periods of disruption.
COVID-19 outcome. To compare life-years associated with
timely cancer surgery with those afforded by hospitalisation
of COVID-19 patients, we modelled a volume of community-
ascertained COVID-19 infection, resulting in an equivalent
volume of hospital admissions to cancer surgeries (see
supplementary Table S1, available at Annals of Oncology
online).
Resource. We analysed health care resource units (HCRUs)
focused specifically on frontline medical and nursing staff,
where one HCRU is one 12-hour shift of direct nursing or
medical care. We upweighted for shifts from health care
workers of high salary (senior doctors) and/or of current
scarcity (anaesthetists, ICU nurses). We calculated HCRUs
per patient using estimated staffing ratios for theatres, ICU
and ward care and operation-specific data for theatre hours,
ICU stay and ward days from oncology centres.Volume 31 - Issue 8 - 2020
A. Sud et al. Annals of OncologyDetails of assumptions and parameter estimates are
detailed in Table 1 and supplementary Table S1, available at
Annals of Oncology online. Analyses were performed using
STATA (version 15; StataCorp, College Station, TX) and tran-
scribed to Excel (Microsoft, Redmond,WA), to provide a full
visibility of parametrisation, model outputs and opportunity
for the reader to customise parameters (supplementary
Materials, available at Annals of Oncology online).
RESULTS
Impact of surgical delay on survival for different cancers
The greatest rates of deaths arise following even modest
delays to surgery in aggressive cancers, with >30% reduc-
tion in survival at 6 months and >17% reduction in survival
at 3 months for patients with stage 2 or 3 cancers of the
bladder, lung, oesophagus, ovary, liver, pancreas and
stomach (Table 2; see also supplementary Table S3 and
supplementary Materials, available at Annals of Oncology
online). Accounting for nosocomial COVID-19 infection, for
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Volume 31 - Issue 8 - 2020surgery by 3 months had a minimal impact on survival: <1%
for all stage 1 ERþ and HER2þ breast cancers, for example.
In older patients (aged >70), for early stage colorectal,
kidney and ERþ breast cancers, the current impact on
survival of COVID-related mortality exceeded the impact of
3 or even 6 months’ delay (Table 2; see also supplementary
Table S3, available at Annals of Oncology online).
For a high proportion of solid cancers, survival at 5 years
is generally considered to be equivalent to cure. Predi-
cated on this assertion, we considered LYGs adjusting for
resource [resource-adjusted life-years gained (RALYGs)].
Perhaps unsurprisingly, most benefit is afforded in younger
age groups for operations that are shorter with no asso-
ciated ICU requirement. For example, trans-urethral
resection of stage 1 bladder cancers affords on average
23.4 RALYGs per patient aged 30e39, whereas cystectomy
for stage 2 bladder cancer is only associated with 1.2
RALYGs in that age group (supplementary Table S4,
available at Annals of Oncology online). In the context of
prioritisation, avoidance of a 6-month delay restitutes on
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Table 2. Reduction in 5-year net survival as a consequence of 6-month delay to surgery for 13 cancer types, by tumour stage and age of diagnosis
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Reduction in survival above the median is represented in red, at the median in yellow and below the median in green. Survival analysis is based on per-day hazard ratios for
disease fatality.
a Strata estimates of lower confidence whereby crude rather than net survival estimates were applied.
Annals of Oncology A. Sud et al.0.7 in the latter (Table 3; see also supplementary Table S5,
available at Annals of Oncology online). Wide local excision
for breast cancer has low resource requirement and
therefore confers substantial RALYGs, even in good prog-
nosis subtypes.Impact of surgical delay on cancer survival combined
across cancer types
Each year, 94 912 surgical resections for common invasive
adult cancer types are performed in England, with 80 406 of
those patients surviving their cancer at 5 years. A surgical
delay of 3months across all incident solid tumours over 1 year
would incur 4755 excess deaths, escalating to 10 760 excess
deaths for a 6-month delay. This includes at 6 months,
attributable deaths of 2980 for colorectal cancer, 1439 for lung
cancer and 804 for breast cancer (Figure 1 and supplementary
Table S6, available at Annals of Oncology online).
For a high proportion of solid cancers, 5-year survival is
generally considered to be equivalent to cure. Predicated
on this assertion, across all cancers a treatment delay of
3 months would lead to a reduction of 92 214 life-years,1068 https://doi.org/10.1016/j.annonc.2020.05.009whereas a treatment delay of 6 months would lead to a
reduction of 208 275 life-years (Table 3). Prior to the
COVID-19 crisis, each year cancer surgery was directly
responsible for 1 717 051 LYGs. This represents on average
18.1 LYG per patient, which reduces to 17.1 with 3 months’
delay and to 15.9 with 6 months’ delay. Cancer surgery per
year requires 764 765 units of health care resource.
Assuming this to be unchanged by delay, this affords on
average 2.25 RALYGs per patient under standard conditions,
reducing to 2.12 with 3 months’ delay and 1.97 with 6
months’ delay, an average loss of 0.12 and 0.27 RALYGs,
respectively, per patient.Resource comparison for outcomes afforded by cancer
surgery and COVID-19 management
For contextualisation, we compare the impact of cancer
surgery delaywith hospital care for patients with community-
acquired COVID-19 infection. COVID-19 ICU admission for
those aged 40e49 yielded on average 27.5 LYGs and 0.8
RALYGs. Those aged >80 admitted to ICU benefit by on
average 2.1 LYGs and 0.06 RALYGs. For non-ICU admission,Volume 31 - Issue 8 - 2020
Table 3. Estimated average life-years gained per unit of health care resource for cancer surgery for 13 cancer types, by tumour stage and age of diagnosis
comparing current surgery with surgery after 6 months’ delay based on 5-year net survival
HCRUs, health care resource units; LYG, life-year gained.
a Strata estimates of lower confidence whereby crude rather than net survival estimates were applied. Values for LYG per HCRU above the median are represented in blue, at the
median in white and below the median in red.
A. Sud et al. Annals of Oncologyaverage benefit is 9.3 LYGs and 1.5 RALYGs for those aged
40e49 and 1.4 LYGs and 0.2 RALYGs for those aged>80 years
(supplementary Materials, available at Annals of Oncology
online). These estimates are inherently conservative as they
do not take into account the impact on life expectancy of the
excess comorbidities associated with many hospitalised
COVID-19 cases.
COVID-19 community-acquired infection of 683 083
individuals would result in 94 912 hospital admissions (i.e.
the equivalent number to number of annual admissions
for cancer surgery; Table 4). For these 94 912 admissions,Volume 31 - Issue 8 - 202016 135 will require ICU (critical cases) and 78 777 will not
require ICU (severe cases); 1 052 949 HCRUs are required
in total and there are 15 587 deaths, 25 752 attributable
lives saved and 482 022 attributable LYGs (8241 deaths/
7894 attributable lives saved/223 227 LYGs for ICU ad-
missions; 7346/17 858/258 795 for non-ICU). This repre-
sents on average 5.08 LYGs and 0.46 RALYGs per
hospitalised COVID-19 patient.
It is therefore noteworthy that a delay of surgery by 6
months results in 208 275 lost life-years for an annual
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Figure 1. Impact from 6-month delay lasting 1 year for all solid cancers analysed and six common cancer types in England expressed in (A) attributable deaths and
(B) life-years lost.
Annals of Oncology A. Sud et al.482 022 LYGs from hospitalisation of an equivalent
number of community-acquired COVID-19 cases. This rises
to 59% when adjusted for differences in resource
(RALYGs).Sensitivity analysis
The outcomes from the model were mostly sensitive to
changes in the Fatality HR for the per-day delay: varying this
by 8% (1SD) caused the average LYGs with a 6-month
1070 https://doi.org/10.1016/j.annonc.2020.05.009delay to range from 15.7 to 16.1, and attributable LYs lost
by 2.00e2.39. Sensitivity analysis for other parameters is
shown in supplementary Table S2, available at Annals of
Oncology online.
DISCUSSION
We provide estimates derived from reported surgical out-
comes to quantify the impact on survival of delay of cancer
treatment, within the parameters of the assumptions of the
model.Volume 31 - Issue 8 - 2020
Table 4. Summary outcomes from delays in cancer surgery, with comparison to an equivalent number of admissions for community-acquired COVID-19
infection. Only major resections for common adult cancers are included
Cancer Surgery 
Reference period (mo) 12 24 
Per patient delay (mo)  3 6 3 6 
Per-day rate of nosocomial infection (current) 0.05 
Standard 
conditions 
Major resections for cancer (total) 94,911.60 189,823.20 
HCRUs (total) 764,764.53 1,529,529.06 
LY gained (total) 1,717,051.14 3,434,102.28 
Lives saved (total) 80,405.76 160,811.52 
LY gained from cancer treatment 
(average per patient) 18.09 
LY gained from cancer treatment 
per HCRU (average per patient) 2.25 
Impact of 
delay 
Deaths attributable to delay (total) 4,755.31 10,760.40 9,510.62 21,520.79 
LY lost attributable to delay (total) 92,213.82 208,274.66 184,427.63 416,549.32 
LY gained from cancer treatment 
postdelay (average per patient) 17.12 15.90 17.12 15.90 
LY lost attributable to delay 
(average per patient) 0.97 2.19 0.97 2.19 
LY gained per HCRU from cancer 
treatment postdelay (average per 
patient) 
2.12 1.97 2.12 1.97 
LY lost per HCRU attributable to 
delay (average per patient) 0.12 0.27 0.12 0.27 
Hospitalisation of community-acquired COVID infection 
Reference period (mo) 12 24 
Community infections 683,083.40 1,366,166.81 
Hospital admissions 
Total admissions 94,911.60 189,823.20 
ICU admissions 16,134.97 32,269.94 
non-ICU admissions 78,776.63 157,553.26 
Health care resource units 
(HCRUs) 
Total 1,052,949.29 2,105,898.58 
ICU 556,656.53 1,113,313.07 
non-ICU 496,292.76 992,585.51 
Deaths 
Total 15,586.52 31,173.04 
ICU 8,240.66 16,481.31 
non-ICU 7,345.86 14,691.73 
Total lives saved 
(attributable to hospital 
admission) 
All 25,752.01 51,504.02 
ICU 7,894.32 15,788.63 
non-ICU 17,857.69 35,715.38 
Total LY gained 
(attributable to hospital 
admission) 
All 482,022.07 964,044.14 
ICU 223,226.82 446,453.63 
non-ICU 258,795.25 517,590.51 
LY gained  




LY gained per HCRU  





LY lost through 'delay' in cancer 
treatment as a proportion of LY 
gained from hospitalisation from 
COVID-19
0.19 0.43 0.19 0.43
RALY lost through 'delay' in 
cancer treatment as a proportion 
of RALY gained from 
hospitalisation from COVID-19
0.26 0.59 0.26 0.59
Reference population: England.
COVID-19, coronavirus disease-2019; HCRUs, health care resource units; ICU, intensive care unit; LY, life-years; RALYs, resource-adjusted life-years.
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For aggressive cancers, our analysis demonstrates that even
short delays (3 months) have a significant impact on patient
survival. However, even for cancers of comparatively
favourable prognosis, a delay of 6 months will result in
significant summed attributable deaths as many of these
cancers are common. Delay will also result in tumours being
more advanced, meaning not only is survival poorer, but
also the upstaged cancers will be more costly to treat in
terms of both surgery and/or chemotherapy. Furthermore,
resource requirements (e.g. ICU stay) are dramatically
higher for the many who will inevitably present as emer-
gencies such as with obstruction, perforation or acute
bleeding of the gastrointestinal tract.22
Critical to mitigating cancer deaths is recognition that
delay or bottleneck may arise at any point in the linear
patient journey from (i) self-presentation of the symptom-
atic patient to primary care, (ii) primary care review and
referral into secondary care (iii) diagnostic investigation,
and (iv) surgery (or radiotherapy) with curative intent.
Alongside any ‘bulge’ in accumulated cases will be the
normal stream of incident cancer presentations. In the face
of prolonged stress, it will be challenging to provide extra
capacity to address these bulges alongside standard de-
mands. In the short term, to avoid knock-on delays, im-
mediate diversion of supra-normal resource volumes are
required to process the backlog of cases that will have
accrued in the initial months of the pandemic, in which
referrals, investigations and surgeries have been reduced
by up to 80%.1 In the medium-to-long term (over the next
3e24 months), avoidance of delay in cancer surgery should
be of the highest priority: urgent attention is required to
ensure sufficient resourcing for standard capacity of all
pathway elements in primary care, cancer diagnostic and
surgical.
Delay in cancer surgery will have a highly deleterious
health and economic impact. For the most part, the surgery
will still be required (and may be more complex and costly)
but results in rapid diminution of resultant LYGs and
resource-adjusted life-years. Comparing equivalent-sized
hospital populations adjusted for resource, the health
impact of delaying cancer surgery for 6 months will
approximate 60% of health gains of hospitalisations for
community-acquired COVID-19 infection. We need to
consider resourcing in the likely event of sizeable require-
ment for COVID-19 management for a sustained period,
potentially up to 2 years. Although large facilities may be
built/repurposed for COVID-19 management, these facilities
are competing for the same fixed pool of health care
workers that care for non-COVID-19 patients.
Where the rate of nosocomial infection is high, for
older groups in particular, surgery and/or SACT may in the
short-term offer more risk than benefit (see
supplementary Materials, available at Annals of Oncology
online). Active focus is required to establish ‘cold’ sections
of the health care system, with rigorous protocols for staff
screening and shielding protocols. This will serve to1072 https://doi.org/10.1016/j.annonc.2020.05.009minimise nosocomial acquisition and mortality from
COVID-19, to protect staff and also to provide reassurance
to the public regarding uptake of diagnostics and surgery
for cancer.
Urgent review by professional bodies is required
regarding best protection of their staffing groups, and
guidance on surgical and diagnostic practice commensurate
with risk/benefit of the respective procedure.3
Implications for prioritisation among cancer patients
Given an accrued backlog of cases and ongoing tight
competition for resources, decisions regarding surgical pri-
oritisation may be required for a number of years, with
capacity varying geographically and temporally. Recognising
its limitations regarding assumptions and parameters, we
propose a model that provides a rational approach by which
to evaluate across patients of different ages, tumour types
and stages the benefit and resource implications of their
cancer surgery. We highlight in our model those age-stage
groups for which COVID-related mortality currently ex-
ceeds survival benefit for surgery and/or SACT. Although
these and other groups for which benefit is marginal will be
the most rationale to delay, they will nevertheless require
monitoring and surgery downstream. Longitudinal planning,
monitoring of progression, dynamic re-prioritisation and
capacity planning will inevitably be highly challenging.
Broader and international relevance
Although we have used data for England, cancer survival is
broadly similar across most economically developed coun-
tries, so the impact of delay per tumour is broadly appli-
cable across Europe. However, variations in incidence of
cancer, life expectancy and population age structure mean
that predictions regarding total case numbers and LYGs and
life-years lost are more difficult to extrapolate, even when
scaling for relative size of reference population.
Although customised for surgical delay due to the COVID-
19 pandemic, this model could readily be adapted to
quantify the impact of surgical delay due to other causes.
Limitations
As with any model-based analysis, our predictions are
predicated on the validity of assumptions and estimates
used for parameterisation. While we have made use of
observational data, our approach simplifies the complexity
of cancer progression and is solely survival focused. For
health care planning, a more elaborate model capturing
stage shifting may offer additional utility. We base our
analysis on survival data from 2013 to 2017; for some
tumour types, standard of care and survival have evolved
since this time. Our modelling of the benefit of SACT is
simplistic as the scheduling, benefits and immunosup-
pressive consequences vary by chemotherapy regimen.
While we have included in our model the impact of
withholding SACT if nosocomial infection risk is high, we
have not modelled additional reduction in survival fromVolume 31 - Issue 8 - 2020
A. Sud et al. Annals of Oncologydelays in administration of adjuvant therapy. Mortality
from nosocomial COVID-19 infection during surgical
admission or attendance for chemotherapy is based on a
uniform per-day risk of infection: these are simplistic and
will vary dramatically in time ans space. While our
resourcing analysis deliberately focuses on the require-
ment for the direct medical and nursing staff who most
limit health care provision, we acknowledge it does not
capture other ‘costs’ incurred in hospital care, primary
care and social care.
Our model of COVID-19 admissions is limited by avail-
ability of detailed individual-level UK data, in particular for
non-CCU hospital admissions; this model is also conserva-
tive insofar as it disregards impact of comorbidities on life
expectancy for hospitalised COVID-19 patients of comor-
bidities on life expectancy.Further research
Within our current approach, we only estimate the effects
of a specified period of per-patient delay. Contemporaneous
data for NHS (National Health Service) activity offer the
prospect of developing dynamic models to predict the
impact of (i) differential prioritisation of patient groups, (ii)
different patterns of re-presentation of ‘accumulated’ cases
alongside incident cases, and (iii) varying release of bot-
tlenecks in primary care, diagnostics and surgery. Evaluation
is also important for the alternative management ap-
proaches being adopted, such as radiotherapy with curative
intent where surgery is gold standard or a priori hormonal
treatment for prostate and ERþ breast cancers. For any
strategies involving deliberate delay to surgery, models
including re-staging focused on the impact to surgery with
curative intent; analyses are also required to quantify the
impact on mortality of changes to life-extending chemo-
therapy and radiotherapy for patients with stage 4 disease.Conclusion
Compared with COVID-19 management, cancer surgery is
highly impactful in regard to LYGs per resource expended.
Delays in diagnosis and surgery cause exponential burden of
attributable mortality. The COVID-19 pandemic has placed
unprecedented strain on health care provision. It is highly
plausible that surges of population infection, lockdowns,
resource competition, bottlenecks and back logs could recur
over the next 2 years. Supra-normal capacity is required to
manage backlogs of accumulated cancer cases alongside
ongoing incident cases. To avoid a deferred public health
crisis of unnecessary cancer deaths, urgent ringfencing of
substantial resources is required.
ACKNOWLEDGEMENTS
This work uses data that have been provided by patients
and collected by the NHS as part of their care and support.
The data are collated, maintained and quality assured by
the National Cancer Registration and Analysis Service, which
is part of Public Health England (PHE).Volume 31 - Issue 8 - 2020FUNDING
CT, RSH and MEJ are supported by The Institute of Cancer
Research. MEJ additionally received funding from Breast
Cancer Now. BT and AG are supported by Cancer Research
UK [grant number C61296/A27223]. CL is supported by and
CT additionally receives funding from The Movember
Foundation. RSH is supported by Cancer Research UK [grant
number C1298/A8362] and Bobby Moore Fund for Cancer
Research UK. AS is in receipt of an Academic Clinical
Lectureship from National Institute for Health Research
(NIHR) and Biomedical Research Centre (BRC) post-doctoral
support. This is a summary of independent research sup-
ported by the NIHR BRC at the Royal Marsden NHS Foun-
dation Trust and Institute of Cancer Research. The views
expressed are those of the authors and not necessarily
those of the NHS, NIHR or the Department of Health. GL is
supported by a Cancer Research UK Advanced Clinician
Scientist Fellowship Award [grant number C18081/A18180]
and is an Associate Director of the multi-institutional
CanTest Collaborative funded by Cancer Research UK
[grant number C8640/A23385].DISCLOSURE
The authors have declared no conflicts of interest.REFERENCES
1. Cancer referrals fell from 40,000 to 10,000 per week in April. In NHS
Providers 14/05/20. 2020.
2. Kutikov A,Weinberg DS, Edelman MJ, et al. A war on two fronts: cancer
care in the time of COVID-19. Ann Intern Med. 2020;172:756e758.
3. Updated Intercollegiate General Surgery Guidance on COVID-19. Royal
College of Surgeons England; 2020.
4. Endoscopy activity and COVID-19: British Society of Gastroenterology
and Joint Advisory Group guidance e update 03.04.20. 2020.
5. National Cancer Registration and Analysis Service (NCRAS). Public
Health England; 2018.
6. Cancer Treatment Information by Cancer Type. National Cancer Insti-
tute; 2020.
7. ICNARC report on COVID-19 in critical care (24/4/20). Intensive Care
National Audit & Research Centre. 2020.
8. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK
patients in hospital with covid-19 using the ISARIC WHO clinical
characterisation protocol: prospective observational cohort study.
BMJ. 2020;369:m1985.
9. The Epidemiological Characteristics of an Outbreak of 2019 Novel
Coronavirus Diseases (COVID-19). China CCDC; 2020.
10. Report of the WHO-China Joint Mission on Coronavirus Disease 2019
(COVID-19). World Health Organisation; 2020.
11. Lee YH, Kung PT,Wang YH, et al. Effect of length of time from diagnosis
to treatment on colorectal cancer survival: a population-based study.
PLoS One. 2019;14:e0210465.
12. Richards MA, Westcombe AM, Love SB, et al. Influence of delay on
survival in patients with breast cancer: a systematic review. Lancet.
1999;353:1119e1126.
13. Mano R, Vertosick EA, Hakimi AA, et al. The effect of delaying ne-
phrectomy on oncologic outcomes in patients with renal tumors
greater than 4cm. Urol Oncol. 2016;34:239.e231e239.e238.
14. Smith EC, Ziogas A, Anton-Culver H. Delay in surgical treatment and
survival after breast cancer diagnosis in young women by race/
ethnicity. JAMA Surg. 2013;148:516e523.
15. Chu AT, Holt SK, Wright JL, et al. Delays in radical cystectomy for
muscle-invasive bladder cancer. Cancer. 2019;125:2011e2017.https://doi.org/10.1016/j.annonc.2020.05.009 1073
Annals of Oncology A. Sud et al.16. Sánchez-Ortiz RF, Huang WC, Mick R, et al. An interval longer than 12
weeks between the diagnosis of muscle invasion and cystectomy is
associated with worse outcome in bladder carcinoma. J Urol. 2003;169:
110e115. discussion 115.
17. May M, Nitzke T, Helke C, et al. Significance of the time period
between diagnosis of muscle invasion and radical cystectomy
with regard to the prognosis of transitional cell carcinoma of
the urothelium in the bladder. Scand J Urol Nephrol. 2004;38:
231e235.
18. Bleicher RJ, Ruth K, Sigurdson ER, et al. Time to surgery and
breast cancer survival in the United States. JAMA Oncol. 2016;2:
330e339.1074 https://doi.org/10.1016/j.annonc.2020.05.00919. Samson P, Patel A, Garrett T, et al. Effects of delayed surgical resection
on short-term and long-term outcomes in clinical stage I non-small cell
lung cancer. Ann Thorac Surg. 2015;99:1906e1913.
20. Yang C-FJ, Wang H, Kumar A, et al. Impact of timing of lobectomy on
survival for clinical stage IA lung squamous cell carcinoma. Chest.
2017;152:1239e1250.
21. Richards MA, Smith P, Ramirez AJ, et al. The influence on survival of
delay in the presentation and treatment of symptomatic breast cancer.
Br J Cancer. 1999;79:858e864.
22. Elliss-Brookes L, McPhail S, Ives A, et al. Routes to diagnosis for cancer
e determining the patient journey using multiple routine data sets.
Br J Cancer. 2012;107:1220e1226.Volume 31 - Issue 8 - 2020
